In the U.S., the Prosigna Assay is indicated in female breast cancer patients who have undergone surgery in conjunction
with locoregional treatment consistent with standard of care, either as:
Not exact matches
The results show no increase in the risk of
locoregional or systemic recurrence in women
with breast cancer who undergo breast reconstruction
with lipofilling.
Patients
with ER - negative, but not ER - positive, isolated
locoregional recurrence after unilateral breast cancer derive significant benefit from chemotherapy.
[57] The postoperative use of radiotherapy for anorectal melanoma following wide local excision has been reported to be associated
with high rates of
locoregional control (74 % to 82 %) at 5 years,
with nearly all patients avoiding the need for abdominoperineal resection and permanent colostomy.
In these patients, clinical results
with systemic therapy have been less than optimal, and
locoregional therapeutic options, such as limb perfusion and intralesional treatments, have thus been explored.
Preliminary analyses of the results of the first combination trials, which show higher response rates than
with either agent alone, offer some optimism that these
locoregional therapies will find application — as treatment for patients who can not tolerate systemic immunotherapies, to alleviate
locoregional morbidity, and perhaps even to «prime» the immune system.